NCT03322267 2026-03-06
Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
National Taiwan University Hospital
Phase 2 Completed
Clinical Trials
69 trialsNCT07452601 2026-03-05
Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC
Tang-Du Hospital
Phase 2 Not yet recruiting
NCT07039162 2026-02-27
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma
China Medical University Hospital
Phase 2 Recruiting
NCT07403435 2026-02-11
Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT07312578 2025-12-31
Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma
Peking University
Phase 2 Enrolling by invitation
NCT06281886 2025-11-17
Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Active not recruiting
NCT05880082 2025-08-24
PPIO-004-EC001
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Completed
NCT03797625 2025-07-23
Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas
Fudan University
Phase 2 Completed
NCT06490003 2025-07-11
Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma
City of Hope Medical Center
Recruiting
NCT04548440 2025-06-12
Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients
Sun Yat-sen University
Phase 2 Completed
NCT05357846 2025-06-12
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
Sun Yat-sen University
Phase 3 Recruiting
NCT06446726 2025-06-06
Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
Sichuan University
Phase 2 Recruiting
NCT06861777 2025-03-11
Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2/3 Not yet recruiting
NCT04804696 2025-02-21
Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma
Peking University
Phase 2 Terminated
NCT06690476 2024-11-15
Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma
Peking University
Phase EARLY_PHASE1 Recruiting
NCT06138028 2024-07-24
Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer
Qingdao Central Hospital
Phase 2/3 Recruiting
NCT05490719 2024-05-21
A Phase II Study of CRT Combined With QL1706 in ESCC Patients
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT06388135 2024-04-29
Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
Xijing Hospital
Phase 4 Not yet recruiting
NCT02465736 2024-01-16
Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)
Sun Yat-sen University
Phase 3 Unknown
NCT06173986 2023-12-18
Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
Shanghai Chest Hospital
Phase 1/2 Recruiting
NCT03964753 2023-10-10
NTNC
Hebei Medical University Fourth Hospital
Phase 2 Recruiting
NCT05302011 2023-10-10
Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Peking Union Medical College Hospital
Phase 2 Completed
NCT06048926 2023-09-21
Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase NA Enrolling by invitation
NCT05984342 2023-08-09
Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma
Affiliated Cancer Hospital of Shantou University Medical College
Phase 1 Recruiting
NCT05603065 2023-06-29
TINES
First Affiliated Hospital Xi'an Jiaotong University
Phase 4 Unknown
NCT05596890 2022-11-28
PICCRT
Guangdong Provincial People's Hospital
Phase 2 Unknown
NCT05469061 2022-07-21
Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05213312 2022-06-15
Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC
Shanghai Zhongshan Hospital
Phase 2/3 Unknown
NCT04807673 2022-06-01
KEYSTONE-002
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Recruiting
NCT04625543 2022-04-26
Neoadjuvant Immunotherapy to ESCC
Qilu Hospital of Shandong University
Phase 2 Withdrawn
NCT00381706 2021-09-29
Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT03791905 2021-03-23
PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT02272699 2021-03-18
Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma
Peking University
Phase 2/3 Withdrawn
NCT03377400 2020-12-17
Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer
Samsung Medical Center
Phase 2 Unknown
NCT01107639 2020-10-20
Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery
Swiss Cancer Institute
Phase 3 Completed
NCT00047112 2020-03-30
Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer
Federation Francophone de Cancerologie Digestive
Phase 3 Completed
NCT02812641 2019-03-11
Neoadjuvant CCRT With/Without Bevacizumab for Locally Advanced ESCC
National Taiwan University Hospital
Phase 2 Unknown
NCT01591135 2018-10-18
A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma
Fudan University
Phase 3 Completed
NCT03579004 2018-07-06
Neoadjuvant Chemotherapy Followed by Preoperative Chemoradiation in Resectable Squamous-cell Esophageal Cancer
Russian Academy of Medical Sciences
Phase 2 Unknown
NCT01627379 2018-03-02
POWER
AIO-Studien-gGmbH
Phase 3 Terminated
NCT03126708 2018-01-04
Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Metastatic Esophageal Squamous Cell Carcinoma
Peking University
Phase 2 Unknown
NCT02969473 2016-11-21
Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT00190554 2016-09-22
A Trial of Chemotherapy Before and After Surgery for Stage II,III Esophageal Squamous Cell Carcinoma
Japan Clinical Oncology Group
Phase 3 Terminated
NCT00003118 2016-07-04
Surgery With or Without Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00544362 2016-05-30
Fluorouracil, Cisplatin, Cetuximab, and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery
Federation Francophone de Cancerologie Digestive
Phase 1/2 Completed
NCT01854749 2016-02-23
S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study
Fudan University
Phase 2 Completed
NCT02665702 2016-01-28
Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas
Fudan University
Phase 2 Unknown
NCT00861094 2015-12-18
Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer
UNICANCER
Phase 2/3 Completed
NCT00397904 2015-11-25
Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02586753 2015-10-26
Paclitaxel or S1 Plus Cisplatin in Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus
Mianyang Central Hospital
Phase 2 Unknown